Feb 5- A federal judge on Friday said Allergan Plc's planned generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.. They closed up $2.00, or 19.7 percent, at $12.13 on the Nasdaq. District Judge Renée Marie Bumb in Camden, New Jersey said Allergan's proposed generic infringed two of the three Supernus...» Read More
In Wednesday’s Web Extra Pete Najarian reveals why he thinks the solar trade is starting to turn. Also “if you want to get into drugs” Guy Adami has your play.
More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.
Abbott Laboratories Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.
European stocks dropped 1.9 percent on Tuesday, knocked lower by growing fears over the fate of the financial services sector, but a steep fall in oil prices helped the market end above the session's lows.
After a knee-jerk reaction to the downside after the closing bell yesterday to the surprising four-cent miss by Genentech, the shares are rallying big time in the early regular trading session.
Genentech earnings fell short of analysts' expectations, but the company's shares rose slightly in extended trading as the firm lifted its profit forecast for the full year.
Like so many people who knew Bobby Murcer or were fans of his, I was so sad to hear the news that he had passed away. I didn't know the man. And I only have vague childhood memories of then-Dodger Stadium announcer John Ramsey saying, "Bobby Murcer", when the "Yankee for Life" was playing for the Giants and Cubs at Chavez Ravine.
In the Fast Money Web Extra the traders reveal how to play tech earnings, pharma earnings, bank earnings and more in the week ahead.
A few weeks ago I blogged about a couple analysts cautioning investors that shares of Irish drugmaker Elan would be volatile surrounding the Alzheimer's conference the end of this month.That has certainly proven to be the case, especially today as the second firm this week initiates coverage of the stock, but this time with a "Sell" rating.
Big pharma makes strange bedfellows. Pfizer, Merck and Eli Lilly this morning announced they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC firm PureTech Ventures.
One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!
New evidence of the power of the multi-billion dollar impotence drugs. A study just out in the peer-reviewed "British Medical Journal" says that the elderly are having sex more often, possibly due to the popular pills for erectile dysfunction.
Drug developer Eli Lilly will buy SGX Pharmaceuticals for about $64 million in cash in an effort to expand its drug discovery efforts, the companies said Tuesday.
At the risk of being ganged up on by the "Elanians" who will take umbrage with the fact that the biopharma team at Cowen and Company is not initiating coverage of the Irish drugmaker with a "screaming buy," I am blogging about the analysts' 50-page call on the stock today.
German health care group Fresenius plans to buy APP Pharmaceuticals in a $3.7 billion deal to expand into the North American intravenous generic drugs market.
Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...
Ahead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen.
Abbott Laboratories won U.S. approval to sell its drug-coated heart stent called Xience, the company said on Wednesday.
Walgreen, one of the largest U.S. drugstore operators, said that June sales at stores open at least one year rose 3.4 percent, led by general merchandise purchases.
Winning sectors like coal have taken a hit. Who's on top now?